David E. Gerber

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer

Puneeth Iyengar, Zabi Wardak, David E. Gerber et al. · JAMA Oncology · 2017 · 1K citations

Medicine, Oncology, Radiation Oncology +13

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman et al. · The Lancet Oncology · 2016 · 961 citations · Full text

Pharmacy, Oncology, Pharmacology +13

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2021 · 826 citations · Full text

Pharmacy, Immunology, Oncology +17

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Hossein Borghaei, Scott Gettinger, Everett E. Vokes et al. · Journal of Clinical Oncology · 2021 · 661 citations · Full text

Medicine, Oncology, Pharmacology +14